Arcutis Biotherapeutics, Inc.
ARQT
$20.43
-$0.29-1.40%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 164.13% | 196.01% | 412.79% | 451.92% | 546.92% |
| Total Other Revenue | -- | -92.86% | -- | -- | -- |
| Total Revenue | 164.13% | 32.84% | 427.58% | 17.44% | 494.57% |
| Cost of Revenue | 116.28% | 171.19% | 207.44% | 365.57% | 346.39% |
| Gross Profit | 170.18% | 23.11% | 471.41% | 6.30% | 520.62% |
| SG&A Expenses | 18.90% | 16.80% | 18.35% | 23.58% | 26.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.76% | 11.31% | 5.75% | 11.74% | 12.48% |
| Operating Income | 70.82% | 22.43% | 87.52% | -5.86% | 24.99% |
| Income Before Tax | 70.30% | 29.31% | 84.21% | 0.49% | 26.28% |
| Income Tax Expenses | -- | -13.89% | 1,192.00% | -- | -- |
| Earnings from Continuing Operations | 69.64% | 29.17% | 83.72% | 7.21% | 26.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.64% | 29.17% | 83.72% | 7.21% | 26.28% |
| EBIT | 70.82% | 22.43% | 87.52% | -5.86% | 24.99% |
| EBITDA | 71.63% | 31.56% | 88.20% | -3.06% | 24.58% |
| EPS Basic | 70.48% | 37.60% | 87.93% | 53.92% | 63.33% |
| Normalized Basic EPS | 71.12% | 37.71% | 88.29% | 50.57% | 63.33% |
| EPS Diluted | 70.48% | 37.60% | 87.93% | 53.92% | 63.33% |
| Normalized Diluted EPS | 71.12% | 37.71% | 88.29% | 50.57% | 63.33% |
| Average Basic Shares Outstanding | 2.85% | 13.50% | 34.93% | 101.37% | 101.01% |
| Average Diluted Shares Outstanding | 2.85% | 13.50% | 34.93% | 101.37% | 101.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |